INFLIXIMAB AND TUMOUR NECROSIS FACTOR ALPHA MEASUREMENT ON INTESTINAL MUCOSA: A NEW TOOL FOR THE CLINIC?
Background: Infliximab (IFX) trough levels measurement could partially explain mechanisms of loss in response to this drug. However, little information exists on its concentration at the mucosal level or mucosal pharmacokinetics. Objective: The aim of this study was to investigate whether IFX cou...
Main Authors: | Silvia Pecere, Valentina Petito, Arianna Amato, Andrea Poscia, Alessandro Armuzzi, Loris Riccardo Lopetuso, Alessandro Sgambato, Giovanni Cammarota, Alfredo Papa, Antonio Gasbarrini, Franco Scaldaferri |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2016-12-01
|
Series: | European Medical Journal Gastroenterology |
Subjects: | |
Online Access: | https://www.emjreviews.com/gastroenterology/article/infliximab-and-tumour-necrosis-factor-alpha-measurement-on-intestinal-mucosa-a-new-tool-for-the-clinic/ |
Similar Items
-
T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis
by: Sara Pratesi, et al.
Published: (2019-01-01) -
Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
by: Akihiro Koga, et al.
Published: (2018-04-01) -
Risk Assessment in Developing KFX/IFX Fighter
by: Bilqis Fitria Salsabiela, et al.
Published: (2017-12-01) -
Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
by: van der Maas Aatke, et al.
Published: (2012-09-01) -
Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)